Meta-analysis · 2025
Silodosin in Treating Men With BPH-Associated Lower Urinary Tract Symptoms: A Systematic Review and Network Meta-Analysis
Li J, Ai C, Yuan C, Wang K, Yu L, Jian Z, Luo Q, Ma X (2025). Silodosin in Treating Men With BPH-Associated Lower Urinary Tract Symptoms: A Systematic Review and Network Meta-Analysis. International Journal of Surgery. doi:10.1097/JS9.0000000000004023
Across 25 randomised trials (6,831 men) of prostate-enlargement medicines, silodosin improved urinary symptoms most but sharply raised the risk of retrograde ejaculation compared with placebo (risk ratio 24.94).
Summary
Alpha-blockers relax the muscle around the prostate and bladder neck and are widely used for urinary symptoms caused by benign prostatic hyperplasia (BPH, an enlarged prostate). This network meta-analysis compared silodosin, a highly selective alpha-blocker, with placebo, tamsulosin, naftopidil and alfuzosin, using 25 randomised controlled trials with 6,831 men.
Silodosin ranked highest for improving urinary symptoms, especially voiding (emptying) symptoms. It was associated with more side effects overall than tamsulosin (risk ratio 1.26) and with a much higher risk of retrograde ejaculation than placebo (risk ratio 24.94). The authors conclude that silodosin is effective but carries an elevated risk of ejaculatory dysfunction, and that clinicians should weigh the benefits against side effects.
Limitations
The analysis was published online ahead of print in 2025. A risk ratio describes relative risk; the abstract does not give the absolute percentage of men affected. The trials were in older men with BPH, not in men taking alpha-blockers for other reasons.
What it means for you
If you take a medicine for an enlarged prostate and notice little or no fluid at orgasm, the medicine is a likely reason. It is usually not harmful, but talk to your doctor: alternatives exist if it bothers you or you are trying to conceive. Do not stop a prescribed medicine on your own.